F.D.A. Fully Approves Pfizer Vaccine

Business

The New York Times 23 August, 2021 - 07:07pm 59 views

The move was expected to kick off a round of new vaccination mandates from hospitals, schools and private companies.

WASHINGTON — The Food and Drug Administration on Monday granted full approval to Pfizer-BioNTech’s coronavirus vaccine for people 16 and older, a decision that is likely to set off a cascade of vaccine requirements by hospitals, colleges and universities, corporations and other organizations.

Within hours, the Pentagon, CVS, the State University of New York system and the New York City school system, among others, announced that they would enforce mandates they had prepared but made contingent on the F.D.A.’s action.

The approval came as the nation’s fight against the pandemic has intensified again, with the highly infectious Delta variant biting deeply into the progress that the country had made over the first half of the year. The Biden administration hopes the development will motivate at least some of the roughly 85 million Americans who are eligible for shots but have so far rejected them to change their minds.

The regulatory move goes a step beyond the emergency use authorization that the agency granted in December. More than 92 million people have already been fully vaccinated since then with Pfizer doses. Some who have rejected the vaccines, expressing fears that they are experimental, have said they wanted to wait until the agency spent more time studying their safety and fully approved them.

In a roughly 10-minute address on the approval, President Biden said it should sweep away any lingering doubts about vaccines and spur more mandates. Appealing to corporate, state and local leaders, he said: “Do what I did last month. Require your employees to get vaccinated or face strict requirements.” In late July, he announced that all federal employees and on-site contractors must be vaccinated against the coronavirus or be required to submit to regular testing and other measures.

Mr. Biden tried to cast the F.D.A. approval as an example of how his administration was making headway against the pandemic, despite overflowing intensive care units in some states and an average of more than 1,000 lives a day lost. He said the death toll, while rising, was still far lower than it was last winter, because more than nine in ten older Americans are now vaccinated.

With the F.D.A. yet to authorize a vaccine even on an emergency basis for children younger than 12, Mr. Biden also tried to reassure anxious parents about the growing number of children who are getting infected with the Delta variant, saying that severe Covid-19 cases in that age group are still “very, very rare.” He also promised to soon address “how we get our kids back to school safely.”

The F.D.A., which has been under pressure to speed up its evaluations of coronavirus vaccines, gave full approval to Pfizer’s just 97 days after the company submitted the last of what regulators said were hundreds of thousands of documents. Officials said they were able to decide the matter in less than half the usual time because regulators worked nights and weekends and added staff members, not because they cut corners.

“This is a pivotal moment for our country in the fight against the pandemic,” Dr. Janet Woodcock, the acting F.D.A. commissioner, told reporters. “The public can be confident that this vaccine meets the F.D.A.’s gold standard for safety, effectiveness, and manufacturing quality that we require for an approved product.”

Some health experts are worried that the approval will unleash a wave of demands from vaccine recipients who want their doctors to prescribe booster doses. The federal government plans to begin rolling out third shots to people who had their second shot eight months earlier, but only after the F.D.A. clears extra doses and not until Sept. 20.

“I think we just have to keep people calm,” said Dr. Jesse L. Goodman, a former chief scientist at the F.D.A. and now a medical professor at Georgetown University. He noted that more than one million Americans had already managed to get extra shots on their own and that demand could be difficult to control.

Ordinarily, final approval could give doctors a certain measure of freedom to prescribe a drug differently than the label advises. Pfizer is also ostensibly now free to market the vaccine, under the brand name Comirnaty.

In this case, though, as both Pfizer and the F.D.A. noted, the federal government controls the distribution of the vaccine in the United States. Dr. Woodcock strongly discouraged people from seeking a third shot until the F.D.A. has ruled on whether extra shots are safe and effective for the general adult population.

She specifically warned against giving the vaccine to children under 12, saying that doing so would be “of great concern” because regulators have not collected enough data yet from clinical trials on safety or the proper dose. Trials are still in progress for that age group, and a regulatory decision about emergency use could be several months away.

“We certainly want to make sure that we get it right in the children ages 5 through 11,” said Dr. Peter Marks, the F.D.A.’s top vaccine regulator, “and then even in younger children after that.”

The vaccine is still authorized for emergency use, instead of fully approved, for children 12 to 15.

Pfizer said it presented the F.D.A. with data from 44,000 clinical trial participants — half of whom got the vaccine, the other half a placebo — in the United States, the European Union, Turkey, South Africa and South America. The F.D.A. said the data showed the vaccine was 91 percent effective in preventing disease. That was a slight drop from the 95 percent efficacy rate in December, when the vaccine was cleared for emergency use. Pfizer said the decrease reflected the fact that researchers had more time to catch people who became sick.

Some public health experts were hopeful that the decision could push some of those hesitant about getting vaccinated off the fence.

Even if only 5 percent more Americans were persuaded to get shots, as some experts have predicted, “that’s still a huge slice of people,” said Dr. Thomas Dobbs, the chief health officer for Mississippi. Like a number of other Southern states, his has been ravaged by the Delta variant. He said licensure would help “shake loose this false assertion that the vaccines are an ‘experimental’ thing.”

A recent poll by the Kaiser Family Foundation, which has been tracking public attitudes during the pandemic, found that three of every 10 unvaccinated people said they would be more likely to get vaccinated with a shot that had been fully approved. But the pollsters and other experts warned that far fewer Americans might actually be swayed by the approval.

“I think that is a vanishingly small number of people in real life” who would change their minds because of the vaccine’s regulatory status, said Alison Buttenheim, an associate professor of nursing at the University of Pennsylvania and an expert on vaccine hesitancy. But if full approval spurs more requirements from employers and other organizations, she said, the results could be more significant.

“We still have a lot of people who just haven’t gotten around to it or don’t have huge objections, but no one’s told them they have to” get vaccinated, she said. “Mandates simplify things for people.”

Already on Monday, the Pentagon announced that the country’s 1.4 million active-duty troops would have to be vaccinated, and Gov. Philip D. Murphy of New Jersey said that all teachers in that state would have to get shots or submit to weekly testing. Chevron and CVS both said they would require some of their employees to receive coronavirus vaccines, and the State University of New York and the University of Minnesota systems announced similar requirements for students.

Wall Street rose, with investors buoyed by the vaccine news. The S&P 500 stock index was up almost 1 percent, and shares of Pfizer climbed 2.5 percent.

So far, 54 percent of Americans who have been fully inoculated have gotten Pfizer shots. Most of the rest received Moderna’s vaccine, which also requires two doses.

Dr. Marks said that federal health agencies would continue to monitor the Pfizer vaccine’s safety. The F.D.A. will also require Pfizer to continue to study the risk of myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the membrane surrounding the heart, in people who get its shot, including long-term outcomes for those who fall ill after vaccination. The F.D.A. in June attached warnings to the Pfizer and Moderna vaccines noting possible increased risk of both conditions after the second dose.

Less than two months after it appeared to have curbed the spread of the virus, the United States is averaging around 150,000 new cases a day and more than 90,000 hospitalized Covid-19 patients. Exactly two months ago, before the Delta variant fully took hold, federal health experts said the nation would be highly unlikely to again face a death toll of 1,000 or more people a day. The seven-day average as of Sunday was 1,008 daily deaths, according to a New York Times database.

“Full approval could not come at a more important time,” said Dr. Richard Besser, the president of the Robert Wood Johnson Foundation and a former acting director of the Centers for Disease Control and Prevention. He called on schools and businesses to require vaccination before allowing people to congregate indoors.

Vaccination rates have been rising steadily in recent weeks as fear of the Delta variant has grown. Providers were administering about 837,000 shots a day late last week, and Mr. Biden said the most recent seven-day total was the highest since early July. He said more people in Alabama, Arkansas, Louisiana and Mississippi — some of the states with the highest caseloads — got their first shots in the past month than in the previous two months combined.

Dr. Marks said that myths about the vaccines remain a major impediment to fighting the pandemic, including false claims that shots would cause infertility, would foster rather than prevent Covid-19, and had even led to thousands of deaths.

“Let me be clear: These claims are simply not true,” he said.

The F.D.A. is in the midst of a blizzard of decisions about coronavirus vaccines. The next major one looming is whether to authorize booster shots.

The Biden administration said last week it planned to offer third shots to adults who got the Pfizer and Moderna vaccines, eight months after their second injection, starting Sept. 20. Third shots are already authorized for some people with immune deficiencies, but the risk-benefit calculus is different for the general population.

Federal health officials said that both Pfizer’s and Moderna’s vaccines, which rely on similar technology, wane in potency over time. That trend, they said, is converging with the rise of the particularly dangerous Delta variant, making those who completed their vaccinations at the start of the year increasingly vulnerable to infection.

Some public health experts have challenged the plan for booster shots as premature. They say the available data shows that the vaccines are holding up well against severe disease and hospitalization, including against the Delta variant. Extra shots would be warranted only if the vaccines failed to meet that standard, some have said.

Regulators are still reviewing Moderna’s application for full approval of its vaccine, which it filed in June, a month after Pfizer. That decision could take several weeks. Johnson & Johnson is expected to apply for full approval soon.

Read full article at The New York Times

FDA Approves First COVID-19 Vaccine

FDA.gov 31 December, 1969 - 06:00pm

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval. 

Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. The result of a person receiving this vaccine is that their immune system will ultimately react defensively to the virus that causes COVID-19. The mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individual’s genetic material. Comirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart. 

The first EUA, issued Dec. 11, for the Pfizer-BioNTech COVID-19 Vaccine for individuals 16 years of age and older was based on safety and effectiveness data from a randomized, controlled, blinded ongoing clinical trial of thousands of individuals. 

To support the FDA’s approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population. 

Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease. 

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.

Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.

The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.

The FDA granted this application Priority Review. The approval was granted to BioNTech Manufacturing GmbH.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Opinion | Why the FDA's full approval of the Pfizer-BioNTech vaccine could be a turning point

The Washington Post 23 August, 2021 - 09:40pm

Champagne Papi found himself to be quite the hot topic over the weekend. Drake trended on Twitter after fellow rapper Kanye West shared the emcee’s home address in a now-deleted Instagram post.

What led to West suddenly leaking the “Hotline Bling” rapper’s personal information? It seems to have started when, while appearing on Trippie Redd‘s new song, “Betrayal,” Drake took some shots at West.

He raps in a verse: “All these fools I’m beefin’ that I barely know / Forty-five, forty-four (burned out), let it go / Ye ain’t changin’ sh-t for me, it’s set in stone.”

This clearly must have gotten back to West, who took to social media to clap back.

Before leaking Drake’s address, West took to Instagram and shared a screenshot seemingly referencing his latest feature. West sent a photo of The Joker, the popular comic book character played by Joaquin Phoenix in the 2019 movie, to an unidentified group thread on iMessage.

Then he wrote in a message: “I live for this. I’ve been f—-d with by nerd ass jock n—as like you my whole life. You will never recover. I promise you.”

Kanye West texts Drake vague threats in a group message after adding Pusha T to the chat pic.twitter.com/ZkNr79xz6q

— The Daily Dose (@DailyDose) August 21, 2021

Kanye West just DOXED Drake ‘s Address! #DramaAlert pic.twitter.com/UWydFsSumA

— KEEM 🍿 (@KEEMSTAR) August 23, 2021

On Sunday, however, West seemed to take it one step further, posting a picture of Drake’s exact location via Google Maps on IG, effectively leaking his address. While the post was almost immediately deleted, that certainly didn’t stop people from taking screenshots, plenty of which are now circulating online.

Fans immediately took to Twitter to react to the shocking revelation.

One user wrote in a tweet, “did kanye just post drakes address and then delete it like nothing happened?”

Others seemed tickled by the fact that West’s long-awaited album, Donda, seemingly keeps getting pushed back, but he had time to leak Drake’s address. A fan wrote, “his man kanye dropped drakes addy before donda,” along with crying emojis.

did kanye just post drakes address and then delete it like nothing happened? 💀 pic.twitter.com/q1y4jZAteh

— ken (@kenxvd) August 23, 2021

While West’s move was certainly shocking, Drake seems to want fans to know he is getting the last laugh.

Hours after West shared the info, Drake shared a video to his Instagram Story in which he is riding around in a car, simply laughing to himself. Fans immediately saw this as a response to West’s move, with Drake keeping it light and seemingly unbothered.

— West Sub Ever (@WestSubEver) August 23, 2021

West and Drake have a long and colored history together. While the exact root of their feud remains a bit murky, Drake did open up about their beef while on LeBron JamesThe Shop back in 2018.

He shared at the time that he believed West played a part in Drake’s infamous feud with Pusha T, sharing, “I’m in Wyoming. I play him ‘March 14.’ I send him a picture of my son. I tell him I’m having trouble with my son’s mother,” all of which wound up on Pusha T’s 2018 diss track “The Story of Adidon.”

Check out his explanation from The Shop below.

The post Drake trends after Kanye West shares his home address on Instagram appeared first on TheGrio.

Single appears on Redd’s expanded edition of new album 'Trip at Knight'

Drake's verse on "Betrayal" may have ruffled a few feathers. After he suggested Kanye West is "burned out," the rapper reportedly posted Drake's home address on social media.

Facebook and Instagram have also shared their support for Lizzo.

Is Iggy Azalea spending one-on-one time with Khloe Kardashian's ex? The rapper sounded off on why she's "actually annoyed" about the rumors involving Tristan Thompson.

Kramer finalized her divorce from Caussin late last month. “Jana has really taken this time to be there for her kids and be a great mom," a source tells PEOPLE

In case you’ve missed it, Gabrielle Union has been absolutely killing it lately. From signing on to produce George M. Johnson’s bestselling memoir All Boys Aren’t Blue to recently optioning Tamara Winfrey-Harris’s award-winning book The Sisters Are Alright: Changing the Broken Narrative of Black Women In America, she is taking critically important themes in today’s society and bringing them to the big—and small—screen.

Vanessa and Natalia Bryant shared throwback photos of Kobe Bryant in honor of his 43rd birthday

Who knew so many people were into high-class art? 😳View Entire Post ›

Chrissy Teigen is no stranger to controversy and now the cookbook author is coming clean about being a “functioning alcoholic” […] The post Chrissy Teigen reveals she was ‘basically a functioning alcoholic’ when she first met husband John Legend appeared first on TheGrio.

This is the system players agreed to.

Colin Hanks says his kids have no "interest" in how famous grandpa Tom Hanks is.

Tristan Thompson shares son Prince, 4, with ex-girlfriend Jordan Craig

The Hills: New Beginnings star celebrated his birthday on Saturday, a day after a video showed him being attacked in a club

She also picked up a '90s-inspired accordion headband from the store during her shopping trip

This story about Tracee Ellis Ross first appeared in the Down to the Wire issue of TheWrap’s awards magazine. By the time its sixth season was coming to a close, ABC’s “black-ish” was a smooth machine. One of the few broadcast TV shows still able to capture the zeitgeist in the streaming era, the show had more than a dozen Emmy nominations to its name and was being hailed as one of the most relevant and casually incisive series on television. The cast and crew knew the job inside and out. “The e

It looks like a new sex-positive social media site is coming to town. Tyga took to Instagram on August 20 to announce that he would be unveiling his new Myystarr website that's set to compete against the London-based company.

Beverley has gotten traded to the Grizzlies then Timberwolves.

Hiking is experiencing a major uptick this year.

Shad Moss a.k.a Bow Wow, is always full of surprises. The rapper showed off an interesting new do' that sent Twitter into a frenzy.

Business Stories